Biopolym. Cell. 1997; 13(4):328-334.
Viruses and Cell
Mechanisms of HIV-1 mediated neurodegeneration promoted by macrophages and astroglial factors
1Magura I. S., 1Rozhmanova O. M.
  1. Bogomoletz Institute of Physiology, NAS of Ukraine
    4, Bogomolets Str., Kyiv, Ukraine, 01024


Neurological disease is a prominent feature of human immunodeficiency virus type I (HIV-1) infection, usually occurring during the last stages of acquired immunodeficiency syndrome (AIDS). The neurologic cognitive impairment, termed HIV-1-associated cognitive/motor complex (AIDS dementia complex). Astrocytes and microglia. are key participants in mediating the neurologic dysfunction associated with HIV infection of the central nervous systems. The neuropathogenesis of HIV-1 infection is related to secretory neumtoxins from activated HIV-1-infected macrophages The toxins produced by the macropliagcs include glutamate-like neurotoxic molecules, free radicals, cysteine, platelet-activating factor, cylokines, and eicosanoids such as arachidonic acid, and as yet unidentified factors emanating from stimulated macmphagcs and/or reactive astrocytes.


[1] Miedema F, Klein MR. AIDS pathogenesis: a finite immune response to blame? Science. 1996;272(5261):505-6.
[2] Freed EO, Martin MA. The role of human immunodeficiency virus type 1 envelope glycoproteins in virus infection. J Biol Chem. 1995;270(41):23883-6.
[3] Morrow CD, Park J, Wakefield JK. Viral gene products and replication of the human immunodeficiency type 1 virus. Am J Physiol. 1994;266(5 Pt 1):C1135-56.
[4] Cohen J. Likely HIV cofactor found. Science. 1996;272(5263):809-10.
[5] Feng Y, Broder CC, Kennedy PE, Berger EA. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science. 1996;272(5263):872-7.
[6] Oravecz T, Pall M, Norcross MA. Beta-chemokine inhibition of monocytotropic HIV-1 infection. Interference with a postbinding fusion step. J Immunol. 1996;157(4):1329-32.
[7] Schmidtmayerova H, Sherry B, Bukrinsky M. Chemokines and HIV replication. Nature. 1996;382(6594):767.
[8] Trkola A, Dragic T, Arthos J, Binley JM, Olson WC, Allaway GP, Cheng-Mayer C, Robinson J, Maddon PJ, Moore JP. CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5. Nature. 1996;384(6605):184-7.
[9] Meltzer MS, Gendelman HE. Mononuclear phagocytes as targets, tissue reservoirs, and immunoregulatory cells in human immunodeficiency virus disease. Curr Top Microbiol Immunol. 1992;181:239-63.
[10] Gartner S, Markovits P, Markovitz DM, Kaplan MH, Gallo RC, Popovic M. The role of mononuclear phagocytes in HTLV-III/LAV infection. Science. 1986;233(4760):215-9.
[11] Koenig S, Gendelman HE, Orenstein JM, Dal Canto MC, Pezeshkpour GH, Yungbluth M, Janotta F, Aksamit A, Martin MA, Fauci AS. Detection of AIDS virus in macrophages in brain tissue from AIDS patients with encephalopathy. Science. 1986;233(4768):1089-93.
[12] Dhawan S, Weeks BS, Soderland C, Schnaper HW, Toro LA, Asthana SP, Hewlett IK, Stetler-Stevenson WG, Yamada SS, Yamada KM, et al. HIV-1 infection alters monocyte interactions with human microvascular endothelial cells. J Immunol. 1995;154(1):422-32.
[13] Nottet HS, Gendelman HE. Unraveling the neuroimmune mechanisms for the HIV-1-associated cognitive/motor complex. Immunol Today. 1995;16(9):441-8.
[14] Lafrenie RM, Wahl LM, Epstein JS, Hewlett IK, Yamada KM, Dhawan S. HIV-1-Tat protein promotes chemotaxis and invasive behavior by monocytes. J Immunol. 1996;157(3):974-7.
[15] Roulston A, Lin R, Beauparlant P, Wainberg MA, Hiscott J. Regulation of human immunodeficiency virus type 1 and cytokine gene expression in myeloid cells by NF-kappa B/Rel transcription factors. Microbiol Rev. 1995;59(3):481-505.
[16] Finnegan A, Roebuck KA, Nakai BE, Gu DS, Rabbi MF, Song S, Landay AL. IL-10 cooperates with TNF-alpha to activate HIV-1 from latently and acutely infected cells of monocyte/macrophage lineage. J Immunol. 1996;156(2):841-51.
[17] Harrison MJG, McArthur JC. AIDS and neurology. Edinburg: Churchill-Livingstone, 1995. 200 p.
[18] Masliah E. In vivo modeling of HIV-1 mediated neurodegeneration. Am J Pathol. 1996;149(3):745-50.
[19] Masliah E, Achim CL, Ge N, DeTeresa R, Terry RD, Wiley CA. Spectrum of human immunodeficiency virus-associated neocortical damage. Ann Neurol. 1992;32(3):321-9.
[20] Wiley CA, Achim C. Human immunodeficiency virus encephalitis is the pathological correlate of dementia in acquired immunodeficiency syndrome. Ann Neurol. 1994;36(4):673-6.
[21] Navia BA, Jordan BD, Price RW. The AIDS dementia complex: I. Clinical features. Ann Neurol. 1986;19(6):517-24.
[22] Price RW, Sidtis J, Rosenblum M. The AIDS dementia complex: some current questions. Ann Neurol. 1988;23 Suppl:S27-33.
[23] Kure K, Lyman WD, Weidenheim KM, Dickson DW. Cellular localization of an HIV-1 antigen in subacute AIDS encephalitis using an improved double-labeling immunohistochemical method. Am J Pathol. 1990;136(5):1085-92.
[24] Wiley CA, Schrier RD, Nelson JA, Lampert PW, Oldstone MB. Cellular localization of human immunodeficiency virus infection within the brains of acquired immune deficiency syndrome patients. Proc Natl Acad Sci U S A. 1986;83(18):7089-93.
[25] Kure K, Llena JF, Lyman WD, Soeiro R, Weidenheim KM, Hirano A, Dickson DW. Human immunodeficiency virus-1 infection of the nervous system: an autopsy study of 268 adult, pediatric, and fetal brains. Hum Pathol. 1991;22(7):700-10.
[26] Budka H. Neuropathology of human immunodeficiency virus infection. Brain Pathol. 1991;1(3):163-75.
[27] Gray F, Haug H, Chimelli L, Geny C, Gaston A, Scaravilli F, Budka H. Prominent cortical atrophy with neuronal loss as correlate of human immunodeficiency virus encephalopathy. Acta Neuropathol. 1991;82(3):229-33.
[28] Weis S, Haug H, Budka H. Neuronal damage in the cerebral cortex of AIDS brains: a morphometric study. Acta Neuropathol. 1993;85(2):185-9.
[29] Masliah E, Ge N, Achim CL, DeTeresa R, Wiley CA. Patterns of neurodegeneration in HIV encephalitis. J NeuroAIDS. 1996;1(1):161-73.
[30] Everall IP, Luthert PJ, Lantos PL. Neuronal loss in the frontal cortex in HIV infection. Lancet. 1991;337(8750):1119-21.
[31] Ketzler S, Weis S, Haug H, Budka H. Loss of neurons in the frontal cortex in AIDS brains. Acta Neuropathol. 1990;80(1):92-4.
[32] Wiley CA, Masliah E, Morey M, Lemere C, DeTeresa R, Grafe M, Hansen L, Terry R. Neocortical damage during HIV infection. Ann Neurol. 1991;29(6):651-7.
[33] Tenhula WN, Xu SZ, Madigan MC, Heller K, Freeman WR, Sadun AA. Morphometric comparisons of optic nerve axon loss in acquired immunodeficiency syndrome. Am J Ophthalmol. 1992;113(1):14-20.
[34] Nottet HS, Persidsky Y, Sasseville VG, Nukuna AN, Bock P, Zhai QH, Sharer LR, McComb RD, Swindells S, Soderland C, Gendelman HE. Mechanisms for the transendothelial migration of HIV-1-infected monocytes into brain. J Immunol. 1996;156(3):1284-95.
[35] Lipton SA, Gendelman HE. Seminars in medicine of the Beth Israel Hospital, Boston. Dementia associated with the acquired immunodeficiency syndrome. N Engl J Med. 1995;332(14):934-40.
[36] Lipton SA. HIV displays its coat of arms. Nature. 1994;367(6459):113-4.
[37] Eddleston M, Mucke L. Molecular profile of reactive astrocytes--implications for their role in neurologic disease. Neuroscience. 1993;54(1):15-36. Review.
[38] Piani IX, Constant DB, Fgei K, Fontana A. Macrophages in the brain: frends or enemies?. NIPS. 1994; 9:80-4.
[39] Giulian D, Vaca K, Noonan CA. Secretion of neurotoxins by mononuclear phagocytes infected with HIV-1. Science. 1990;250(4987):1593-6.
[40] Takahashi K, Wesselingh SL, Griffin DE, McArthur JC, Johnson RT, Glass JD. Localization of HIV-1 in human brain using polymerase chain reaction/in situ hybridization and immunocytochemistry. Ann Neurol. 1996;39(6):705-11.
[41] Saito Y, Sharer LR, Epstein LG, Michaels J, Mintz M, Louder M, Golding K, Cvetkovich TA, Blumberg BM. Overexpression of nef as a marker for restricted HIV-1 infection of astrocytes in postmortem pediatric central nervous tissues. Neurology. 1994;44(3 Pt 1):474-81.
[42] Tornatore C, Chandra R, Berger JR, Major EO. HIV-1 infection of subcortical astrocytes in the pediatric central nervous system. Neurology. 1994;44(3 Pt 1):481-7.
[43] Hickey WF, Kimura H. Perivascular microglial cells of the CNS are bone marrow-derived and present antigen in vivo. Science. 1988;239(4837):290-2.
[44] Benveniste EN. Inflammatory cytokines within the central nervous system: sources, function, and mechanism of action. Am J Physiol. 1992;263(1 Pt 1):C1-16.
[45] Kreutzberg GW. Microglia: a sensor for pathological events in the CNS. Trends Neurosci. 1996;19(8):312-8.
[46] McGeer PL, Kawamata T, Walker DG, Akiyama H, Tooyama I, McGeer EG. Microglia in degenerative neurological disease. Glia. 1993;7(1):84-92. Review.
[47] Flaris NA, Densmore TL, Molleston MC, Hickey WF. Characterization of microglia and macrophages in the central nervous system of rats: definition of the differential expression of molecules using standard and novel monoclonal antibodies in normal CNS and in four models of parenchymal reaction. Glia. 1993;7(1):34-40.
[48] Weis S, Neuhaus B, Mehraein P. Activation of microglia in HIV-1 infected brains is not dependent on the presence of HIV-1 antigens. Neuroreport. 1994;5(12):1514-6.
[49] Brenneman DE, Westbrook GL, Fitzgerald SP, Ennist DL, Elkins KL, Ruff MR, Pert CB. Neuronal cell killing by the envelope protein of HIV and its prevention by vasoactive intestinal peptide. Nature. 1988;335(6191):639-42.
[50] Dreyer EB, Kaiser PK, Offermann JT, Lipton SA. HIV-1 coat protein neurotoxicity prevented by calcium channel antagonists. Science. 1990;248(4953):364-7.
[51] Lipton SA, Sucher NJ, Kaiser PK, Dreyer EB. Synergistic effects of HIV coat protein and NMDA receptor-mediated neurotoxicity. Neuron. 1991;7(1):111-8.
[52] M?ller WE, Schr?der HC, Ushijima H, Dapper J, Bormann J. gp120 of HIV-1 induces apoptosis in rat cortical cell cultures: prevention by memantine. Eur J Pharmacol. 1992;226(3):209-14.
[53] Savio T, Levi G. Neurotoxicity of HIV coat protein gp120, NMDA receptors, and protein kinase C: a study with rat cerebellar granule cell cultures. J Neurosci Res. 1993;34(3):265-72.
[54] Lipton SA. Requirement for macrophages in neuronal injury induced by HIV envelope protein gp120. Neuroreport. 1992;3(10):913-5.
[55] Aggoun-Zouaoui D, Charriaut-Marlangue C, Rivera S, Jorquera I, Ben-Ari Y, Represa A. The HIV-1 envelope protein gp120 induces neuronal apoptosis in hippocampal slices. Neuroreport. 1996;7(2):433-6.
[56] Toggas SM, Masliah E, Rockenstein EM, Rall GF, Abraham CR, Mucke L. Central nervous system damage produced by expression of the HIV-1 coat protein gp120 in transgenic mice. Nature. 1994;367(6459):188-93.
[57] Lipton SA. HIV displays its coat of arms. Nature. 1994;367(6459):113-4.
[58] Lipton SA. Models of neuronal injury in AIDS: another role for the NMDA receptor? Trends Neurosci. 1992;15(3):75-9.
[59] Dawson VL, Dawson TM, Uhl GR, Snyder SH. Human immunodeficiency virus type 1 coat protein neurotoxicity mediated by nitric oxide in primary cortical cultures. Proc Natl Acad Sci U S A. 1993;90(8):3256-9.
[60] Collingridge GL, Singer W. Excitatory amino acid receptors and synaptic plasticity. Trends Pharmacol Sci. 1990;11(7):290-6.
[61] Bliss TV, Collingridge GL. A synaptic model of memory: long-term potentiation in the hippocampus. Nature. 1993;361(6407):31-9.
[62] Beal MF, Hyman BT, Koroshetz W. Do defects in mitochondrial energy metabolism underlie the pathology of neurodegenerative diseases? Trends Neurosci. 1993;16(4):125-31.
[63] Beal MF. Mechanisms of excitotoxicity in neurologic diseases. FASEB J. 1992;6(15):3338-44.
[64] Schulz JB, Henshaw DR, Siwek D, Jenkins BG, Ferrante RJ, Cipolloni PB, Kowall NW, Rosen BR, Beal MF. Involvement of free radicals in excitotoxicity in vivo. J Neurochem. 1995;64(5):2239-47.
[65] Lipton SA, Choi YB, Pan ZH, Lei SZ, Chen HS, Sucher NJ, Loscalzo J, Singel DJ, Stamler JS. A redox-based mechanism for the neuroprotective and neurodestructive effects of nitric oxide and related nitroso-compounds. Nature. 1993;364(6438):626-32.
[66] Dawson VL, Dawson TM, Bartley DA, Uhl GR, Snyder SH. Mechanisms of nitric oxide-mediated neurotoxicity in primary brain cultures. J Neurosci. 1993;13(6):2651-61.
[67] Koprowski H, Zheng YM, Heber-Katz E, Fraser N, Rorke L, Fu ZF, Hanlon C, Dietzschold B. In vivo expression of inducible nitric oxide synthase in experimentally induced neurologic diseases. Proc Natl Acad Sci U S A. 1993;90(7):3024-7.
[68] Bukrinsky MI, Nottet HS, Schmidtmayerova H, Dubrovsky L, Flanagan CR, Mullins ME, Lipton SA, Gendelman HE. Regulation of nitric oxide synthase activity in human immunodeficiency virus type 1 (HIV-1)-infected monocytes: implications for HIV-associated neurological disease. J Exp Med. 1995;181(2):735-45.
[69] Lipton SA. Prospects for clinically tolerated NMDA antagonists: open-channel blockers and alternative redox states of nitric oxide. Trends Neurosci. 1993;16(12):527-32.
[70] Lee SC, Dickson DW, Liu W, Brosnan CF. Induction of nitric oxide synthase activity in human astrocytes by interleukin-1 beta and interferon-gamma. J Neuroimmunol. 1993;46(1-2):19-24.
[71] Pietraforte D, Tritarelli E, Testa U, Minetti M. gp120 HIV envelope glycoprotein increases the production of nitric oxide in human monocyte-derived macrophages. J Leukoc Biol. 1994;55(2):175-82.
[72] Munir M, Lu L, Mcgonigle P. Excitotoxic cell death and delayed rescue in human neurons derived from NT2 cells. J Neurosci. 1995;15(12):7847-60.
[73] Wu P, Price P, Du B, Hatch WC, Terwilliger EF. Direct cytotoxicity of HIV-1 envelope protein gp120 on human NT neurons. Neuroreport. 1996;7(5):1045-9.
[74] Robbins DS, Shirazi Y, Drysdale BE, Lieberman A, Shin HS, Shin ML. Production of cytotoxic factor for oligodendrocytes by stimulated astrocytes. J Immunol. 1987;139(8):2593-7.
[75] Wahl SM, Allen JB, McCartney-Francis N, Morganti-Kossmann MC, Kossmann T, Ellingsworth L, Mai UE, Mergenhagen SE, Orenstein JM. Macrophage- and astrocyte-derived transforming growth factor beta as a mediator of central nervous system dysfunction in acquired immune deficiency syndrome. J Exp Med. 1991;173(4):981-91.
[76] Gallo P, Frei K, Rordorf C, Lazdins J, Tavolato B, Fontana A. Human immunodeficiency virus type 1 (HIV-1) infection of the central nervous system: an evaluation of cytokines in cerebrospinal fluid. J Neuroimmunol. 1989;23(2):109-16.
[77] Merril JE, Martinez-Maza O. Cytokines in AIDS-associated neurons and immune system disfunction. Neurobiology of cytokines. P B; Methods in neuroscience. Ed. DeSouza E. B. San Diego: Acad, press, 1993: 243-266.
[78] Tyor WR, Glass JD, Griffin JW, Becker PS, McArthur JC, Bezman L, Griffin DE. Cytokine expression in the brain during the acquired immunodeficiency syndrome. Ann Neurol. 1992;31(4):349-60.
[79] Selmaj KW, Raine CS. Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro. Ann Neurol. 1988;23(4):339-46.
[80] Griffin WS, Stanley LC, Ling C, White L, MacLeod V, Perrot LJ, White CL 3rd, Araoz C. Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc Natl Acad Sci U S A. 1989;86(19):7611-5.
[81] Gelbard HA, Nottet HS, Swindells S, Jett M, Dzenko KA, Genis P, White R, Wang L, Choi YB, Zhang D, et al. Platelet-activating factor: a candidate human immunodeficiency virus type 1-induced neurotoxin. J Virol. 1994;68(7):4628-35.
[82] Genis P, Jett M, Bernton EW, Boyle T, Gelbard HA, Dzenko K, Keane RW, Resnick L, Mizrachi Y, Volsky DJ, et al. Cytokines and arachidonic metabolites produced during human immunodeficiency virus (HIV)-infected macrophage-astroglia interactions: implications for the neuropathogenesis of HIV disease. J Exp Med. 1992;176(6):1703-18.
[83] Merrill JE, Benveniste EN. Cytokines in inflammatory brain lesions: helpful and harmful. Trends Neurosci. 1996;19(8):331-8.
[84] Hopkins SJ, Rothwell NJ. Cytokines and the nervous system. I: Expression and recognition. Trends Neurosci. 1995;18(2):83-8.
[85] Rothwell NJ, Hopkins SJ. Cytokines and the nervous system II: Actions and mechanisms of action. Trends Neurosci. 1995;18(3):130-6.
[86] Sakai N, Kaufman S, Milstien S. Parallel induction of nitric oxide and tetrahydrobiopterin synthesis by cytokines in rat glial cells. J Neurochem. 1995;65(2):895-902.
[87] Nottet HS, Jett M, Flanagan CR, Zhai QH, Persidsky Y, Rizzino A, Bernton EW, Genis P, Baldwin T, Schwartz J, et al. A regulatory role for astrocytes in HIV-1 encephalitis. An overexpression of eicosanoids, platelet-activating factor, and tumor necrosis factor-alpha by activated HIV-1-infected monocytes is attenuated by primary human astrocytes. J Immunol. 1995;154(7):3567-81.
[88] Shrikant P, Benos DJ, Tang LP, Benveniste EN. HIV glycoprotein 120 enhances intercellular adhesion molecule-1 gene expression in glial cells. Involvement of Janus kinase/signal transducer and activator of transcription and protein kinase C signaling pathways. J Immunol. 1996;156(3):1307-14.
[89] Shao Y, McCarthy KD. Plasticity of astrocytes. Glia. 1994;11(2):147-55.
[90] Rudge JS. Astrocyte-derived neurotrophic factors. AstroВ­ cytes: pharmacology and function. Ed. S. M. Murphy. New York: Academia, 1993: 267-305.
[91] Mattson MP, Cheng B, Smith-Swintosky VL. Mechanisms of neurotrophic factor protection against calcium- and free radical-mediated excitotoxic injury: implications for treating neurodegenerative disorders. Exp Neurol. 1993;124(1):89-95.
[92] Sugiyama K, Brunori A, Mayer ML. Glial uptake of excitatory amino acids influences neuronal survival in cultures of mouse hippocampus. Neuroscience. 1989;32(3):779-91.
[93] Rosenberg PA, Amin S, Leitner M. Glutamate uptake disguises neurotoxic potency of glutamate agonists in cerebral cortex in dissociated cell culture. J Neurosci. 1992;12(1):56-61.
[94] Rosenberg PA, Aizenman E. Hundred-fold increase in neuronal vulnerability to glutamate toxicity in astrocyte-poor cultures of rat cerebral cortex. Neurosci Lett. 1989;103(2):162-8.
[95] de la Monte SM, Ho DD, Schooley RT, Hirsch MS, Richardson EP Jr. Subacute encephalomyelitis of AIDS and its relation to HTLV-III infection. Neurology. 1987;37(4):562-9.